-
Part 3 | Session 6 ACC 2026 with Dr Mehran: Leadership, Vision, and the Future of the College
-
Part 3 | Session 7 Heart Failure in 2026: Practical Therapy Lessons From ACC.26
-
Part 3 | Session 8 RECOVER-Autonomic - Ivabradine for Post-COVID POTS
-
Part 3 | Session 9 ORBITA-CTO - PCI Versus Placebo for Chronic Total Occlusion in Stable Angina
-
Part 3 | Session 10 CHIP-BCIS3 – Percutaneous LV Unloading in High-Risk PCI
-
Part 3 | Session 11 Dr Reddy & Dr Nair on CHAMPION-AF: Redefining Stroke Prevention
-
Part 3 | Session 12 FAST III - FFR vs vFFR to Guide Revascularisation
-
Part 3 | Session 13 AI-Based Retinal Imaging for Atherosclerotic Cardiovascular Risk
-
Part 3 | Session 14 CORALreef — Durability of Enlicitide for Lipid Lowering in Hypercholesterolaemia
-
Part 4 | Session 1 STEMI-DTU, GOFRESH, and HI-PEITHO
-
Part 4 | Session 2 SURPASS CVOT, HI-PEITHO, SURVIV
-
Part 4 | Session 3 Top Takeaways from the 2026 Dyslipidaemia Guidelines
-
Part 4 | Session 4 3 ACC.26 Highlights for the Cardiology Pharmacist
-
Part 1 | Session 1 CHAMPION-AF: LAA Closure vs OAC in AF Outcomes
-
Part 1 | Session 2 ALERT: Under-treatment in AS and MR
-
Part 1 | Session 3 PRO-TAVI: TAVI With or Without Routine PCI
-
Part 1 | Session 4 Dig-RHD: Digoxin in Rheumatic Heart Disease
-
Part 2 | Session 1 VESALIUS-CV, KARDINAL, CHIP-BCIS3 & More
-
Part 2 | Session 2 CHAMPION-AF, HI-PEITHO, STEMI-DTU
-
Part 3 | Session 1 Door to Unload Randomized Clinical Trial
-
Part 3 | Session 2 ALL-RISE – Coronary Physiology From Angiography vs Pressure Wire for PCI
ACC.26 – Dr Navin Kapur (Tufts Medicine, Boston, MA, US) joins us to discuss findings from the STEMI-Door To Unload (DTU) randomised clinical trial, examining whether primary left ventricular unloading with the Impella CP® device prior to reperfusion can reduce infarct size and heart failure-related outcomes in patients presenting with anterior ST-elevation myocardial infarction.
This prospective, multicentre, randomised controlled trial enrolled 527 patients with acute anterior STEMI across 63 sites in the US, Canada, Europe, and the UK. Patients were randomised to 30 minutes of LV unloading via the Impella CP® device prior to primary PCI, or primary PCI alone as standard of care. The primary endpoint was infarct size normalised to left ventricular mass, assessed by cardiac MRI at 3–5 days post-procedure, with a composite secondary efficacy endpoint — including cardiovascular mortality, cardiogenic shock, LVAD or transplant, heart failure hospitalisation, and ICD/CRT placement — evaluated at 12 months.
Interview Questions:
- What is the rationale for primary LV unloading prior to reperfusion, and how has this concept evolved over recent years?
- What were the key design features of the STEMI-DTU trial and how did you approach the 30-minute unloading protocol?
- What were your primary and key secondary findings?
- How do the results inform the use of mechanical circulatory support in the primary PCI setting?
- What are your take-home messages for interventional cardiologists managing anterior STEMI?
- What are the next steps for this research?
Recorded on-site at ACC Annual Scientific Session 2026, New Orleans
For more expert insights and late-breaking science from ACC 2026, visit the Late-breaking Science Video Collection.
Editors: Jordan Rance
Videographer:
Support: This is an independent interview produced by Radcliffe Cardiology.
Keep up-to-date with our video collection from the American College of Cardiology's 75th Annual Scientific Session, bringing you the latest from late-breaking science, featured research, and clinical horizon sessions.
Catch our congress preview and wrap-up in the NVM Cardiology Meeting Reflections series, alongside concise Expert Interviews with leading faculty distilling the key take-home messages for clinical practice — plus in-depth Highlights breaking down the most impactful trials of the meeting.
More from this programme
Part 1
Late-Breaker Discussions
Part 2
Between the Sessions with Dr Purvi Parwani
Part 3
Expert Interviews
Part 4
Highlights
Part 5
Market Watch
Part 6
NVM Cardiology Meeting Reflections
Faculty Biographies
Navin K Kapur
Associate Professor
Dr Navin K Kapur, MD, FAHA, FACC, FSCAI is Executive Director, The CardioVascular Center for Research and Innovation (CVCRI); Director, Acute Mechanical Circulatory Support Program; Director, Interventional Research Laboratories; Director of Cardiac Biology Research Center, Molecular Cardiology Research Institute (MCRI); Associate Professor, Tufts University School of Medicine.
Dr Kapur's clinical expertise focuses on invasive hemodynamics, mechanical circulatory support, complex percutaneous coronary intervention, and interventional therapies for patients with advanced heart failure. Dr Kapur’s translational research focuses on acute and chronic heart failure, circulatory support device development, and cardioprotective mechanisms in the setting of acute myocardial infarction. His laboratory was the first to identify that first unloading the left ventricle and delaying coronary reperfusion activates a cardioprotective signaling program that reduces myocardial damage during…
Comments